SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Actuate Therapeutics Plans Phase 1/2 Trial of Oral Elraglusib for Q1 2027

Valid market news retained in the public archive without immediate LiveCast distribution.

ACTU

Related stories